Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis
Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Oct 8, 2016
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
Specific Aims: To evaluate the impact of early administration of subcutaneous glargine versus standard care on time of insulin infusion in DKA patients and other secondary outcomes listed in this application.
Methods: DKA patients enrolled in this study will receive the long acting glargine dose (0.3 units/kg with a maximum dose of 30 units) within two hours after initiation the IV insulin infusion. Besides timing of the glargine dose, no other changes in standard patient care will occur in those patients enrolled in this study, the same labs will be collected and the insulin infusion will...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Bicarbonate \<18 mg/dL
- • Anion gap \>16
- • Blood glucose \>250 mg/dL
- • Ketonemia or ketonuria
- Exclusion Criteria:
- • Pregnant women
- • Refused consent
- • Patient left ED against medical advice
About University Of Maryland, Baltimore
The University of Maryland, Baltimore (UMB) is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, UMB leverages its extensive resources and expertise across various disciplines, including medicine, pharmacy, nursing, and social work, to contribute to groundbreaking discoveries and improve patient outcomes. Committed to ethical research practices and collaboration, UMB fosters an environment that promotes the translation of scientific knowledge into real-world applications, ultimately enhancing the well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
George C Willis, MD
Principal Investigator
Director of Undergraduate Medical Education
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials